Product Description
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that functionally antagonises activity of the glucagon receptor (GCGR) in vitro (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9614)
Mechanisms of Action: GcGr Blocker
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
R1193-DM-1402 | P1 |
Terminated |
Type 2 Diabetes |
2015-12-01 |
|
R1193-HV-1219 | P1 |
Completed |
Healthy Volunteers |
2015-01-01 |